Mendus AB: Mendus to participate in upcoming conferences in March 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:
EQT Life Sciences’ BioCapital Europe
Amsterdam, The Netherlands, March 9, 2023
Erik Manting, CEO of Mendus, will attend the conference.
https://www.biocapitaleurope.com/
BIO-Europe Spring 2023
Basel, Switzerland, March 20–22, 2023
Members of Mendus’ leadership team will participate.
https://informaconnect.com/bioeurope-spring/
8th Annual Innate Killer Summit 2023
San Diego, CA, USA, March 27–30, 2023
Erik Manting, CEO of Mendus, will give a presentation and update on Mendus’ novel method for the expansion of memory NK cells.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Fortuna renews share repurchase program30.4.2024 11:00:00 CEST | Press release
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (TSX: FVI) (NYSE: FSM) announced today that the Toronto Stock Exchange has approved the renewal of Fortuna’s normal course issuer bid (the “NCIB”) to purchase up to five percent of its outstanding common shares. Under the NCIB, purchases of common shares may be made through the Toronto Stock Exchange, the New York Stock Exchange and/or alternative Canadian trading systems. The share repurchase program starts on May 2, 2024 and will expire on the earlier of: May 1, 2025; one calendar year after the renewal of the share repurchase program;the date Fortuna acquires the maximum number of common shares allowable under the NCIB; orthe date Fortuna otherwise determines not to make any further repurchases under the NCIB. Fortuna believes that from time to time, its common shares trade at market prices that may not adequately reflect their underlying value. As a result, depending upon future price movement
CDR-Life Announces Fourth Milestone Achievement with Boehringer Ingelheim in Phase 1 Geographic Atrophy Trial30.4.2024 11:00:00 CEST | Press release
ZÜRICH, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the advancement of the Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim (BI) for the treatment of geographic atrophy (GA). This marks the achievement of the fourth milestone under the collaboration and licensing agreement between BI and CDR-Life. BI 771716 is an antibody fragment-based compound. Its reduced size enables optimized retinal layer-penetration to the most critical target site driving GA disease pathology. “We are thrilled by the continued success of our long-term partnership with Boehringer Ingelheim and the progression of BI 771716 in this Phase 1 trial as evident by the achievement of this fourth milestone payment,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “Together with Boehringer Ingelheim, we are hopeful that this candidate has the potential to significantly slow down the progression of GA, bringing a much-need
NetBet Denmark joins forces with Pragmatic Play30.4.2024 10:55:13 CEST | Press release
COPENHAGEN, Denmark, April 30, 2024 (GLOBE NEWSWIRE) -- NetBet Denmark is excited to announce that it is hosting games from influential online casino provider Pragmatic Play. Pragmatic Play has won numerous awards that showcase its commitment to an excellent gaming experience. In 2023, the supplier won dozens of industry accolades, including Slot Provider of the Year at the International Gaming Awards, Casino Software Supplier at the EGR B2B Awards, and Casino/Slots Developer at the SBC Awards. An award-winning selection of, can now be accessed by NetBet Denmark players, along with the latest releases and popular Live Casino titles such as Blackjack, Baccarat and Mega Roulette. NetBet Denmark’s PR manager, Claudia Georgevici, said: "It’s a testament to Pragmatic Play’s abilities that they have won so many awards. These showcase their commitment to provide players with an enjoyable experience, and we look forward to a mutually beneficial and enjoyable relationship." NetBet players can e
NetBet Danmark slår sig sammen med Pragmatic Play30.4.2024 10:55:13 CEST | pressemeddelelse
COPENHAGEN, Denmark, April 30, 2024 (GLOBE NEWSWIRE) -- NetBet Danmark er glade for at kunne annoncere, at de vil tilbyde spil fra den indflydelsesrige online casino udbyder Pragmatic Play. Pragmatic Play har vundet adskillige priser, der viser deres engagement at tilbyde fremragende spiloplevelser. I 2023 vandt udbyderen et hav af industripriser, heriblandt årets spiludbyder ved International Gaming Awards, Casino Software Provider ved EGR B2B Awards og Casino/Slots Developer ved SBC Awards. Et prisvindende udvalg af, kan nu spilles af spillere hos NetBet Danmark, sammen med de nyeste udgivelser og populære Live Casino-titler som Blackjack, Baccarat og Mega Roulette. NetBet Danmarks PR-manager, Claudia Georgevici, udtaler: "Det er et bevis på Pragmatic Plays evner, at de har vundet så mange priser. De viser deres engagement i at give spillere en god oplevelse, og vi ser frem til et gensidigt fordelagtigt og behageligt samarbejde." NetBet-spillere kan udforske de spændende nye spil fra
NAV error30.4.2024 10:47:05 CEST | Press release
Flg. Fonde har i tidsrummet 09.45-10.15 haft NAV fejl: SEIBDP, SEBINVEST AKL BALANCE DEFENSIV P, DK0010273523 Fejl NAV 408,22 Korrekt NAV 153,13 SEIBSP, SEBINVEST AKL BALANCE STABIL P, DK0010273606 Fejl NAV 672,83 Korrekt NAV 186,14 SEIBVP, SEBINVEST AKL BALANCE VÆKST P, DK0010273796 Fejl NAV 1066,8 Korrekt NAV 213,28 Handler kørt på fejl NAV vil blive annulleret. Vi beklager ulejligheden. Såfremt der måtte være spørgsmål til ovenstående kan der rettes henvendelse til Direktør i foreningens administrationsselskab, Lise Bøgelund Jensen på tlf. 33282828 Med venlig hilsen Investeringsforeningen SEB Invest